| 1. |
- Abbafati, Cristiana, et al.
(författare)
-
- 2020
-
Tidskriftsartikel (refereegranskat)
|
|
| 2. |
- Botvinik-Nezer, Rotem, et al.
(författare)
-
Variability in the analysis of a single neuroimaging dataset by many teams
- 2020
-
Ingår i: Nature. - : Springer Science and Business Media LLC. - 0028-0836 .- 1476-4687. ; 582, s. 84-88
-
Tidskriftsartikel (refereegranskat)abstract
- Data analysis workflows in many scientific domains have become increasingly complex and flexible. Here we assess the effect of this flexibility on the results of functional magnetic resonance imaging by asking 70 independent teams to analyse the same dataset, testing the same 9 ex-ante hypotheses(1). The flexibility of analytical approaches is exemplified by the fact that no two teams chose identical workflows to analyse the data. This flexibility resulted in sizeable variation in the results of hypothesis tests, even for teams whose statistical maps were highly correlated at intermediate stages of the analysis pipeline. Variation in reported results was related to several aspects of analysis methodology. Notably, a meta-analytical approach that aggregated information across teams yielded a significant consensus in activated regions. Furthermore, prediction markets of researchers in the field revealed an overestimation of the likelihood of significant findings, even by researchers with direct knowledge of the dataset(2-5). Our findings show that analytical flexibility can have substantial effects on scientific conclusions, and identify factors that may be related to variability in the analysis of functional magnetic resonance imaging. The results emphasize the importance of validating and sharing complex analysis workflows, and demonstrate the need for performing and reporting multiple analyses of the same data. Potential approaches that could be used to mitigate issues related to analytical variability are discussed. The results obtained by seventy different teams analysing the same functional magnetic resonance imaging dataset show substantial variation, highlighting the influence of analytical choices and the importance of sharing workflows publicly and performing multiple analyses.
|
|
| 3. |
- Falster, Daniel, et al.
(författare)
-
AusTraits, a curated plant trait database for the Australian flora
- 2021
-
Ingår i: Scientific Data. - : Nature Portfolio. - 2052-4463. ; 8:1
-
Tidskriftsartikel (refereegranskat)abstract
- We introduce the AusTraits database - a compilation of values of plant traits for taxa in the Australian flora (hereafter AusTraits). AusTraits synthesises data on 448 traits across 28,640 taxa from field campaigns, published literature, taxonomic monographs, and individual taxon descriptions. Traits vary in scope from physiological measures of performance (e.g. photosynthetic gas exchange, water-use efficiency) to morphological attributes (e.g. leaf area, seed mass, plant height) which link to aspects of ecological variation. AusTraits contains curated and harmonised individual- and species-level measurements coupled to, where available, contextual information on site properties and experimental conditions. This article provides information on version 3.0.2 of AusTraits which contains data for 997,808 trait-by-taxon combinations. We envision AusTraits as an ongoing collaborative initiative for easily archiving and sharing trait data, which also provides a template for other national or regional initiatives globally to fill persistent gaps in trait knowledge.
|
|
| 4. |
- Boutry, Céline, et al.
(författare)
-
The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster : Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70
- 2022
-
Ingår i: Clinical Infectious Diseases. - : Oxford University Press. - 1058-4838 .- 1537-6591. ; 74:8, s. 1459-1467
-
Tidskriftsartikel (refereegranskat)abstract
- Efficacy against herpes zoster and immune responses to the adjuvanted recombinant zoster vaccine plateaued at high levels between 5.1 and 7.1 years (mean) post-vaccination, suggesting that its clinical benefit in older adults is sustained for at least 7 years post-vaccination. Background This ongoing follow-up study evaluated the persistence of efficacy and immune responses for 6 additional years in adults vaccinated with the glycoprotein E (gE)-based adjuvanted recombinant zoster vaccine (RZV) at age >= 50 years in 2 pivotal efficacy trials (ZOE-50 and ZOE-70). The present interim analysis was performed after >= 2 additional years of follow-up (between 5.1 and 7.1 years [mean] post-vaccination) and includes partial data for year (Y) 8 post-vaccination. Methods Annual assessments were performed for efficacy against herpes zoster (HZ) from Y6 post-vaccination and for anti-gE antibody concentrations and gE-specific CD4[2+] T-cell (expressing >= 2 of 4 assessed activation markers) frequencies from Y5 post-vaccination. Results Of 7413 participants enrolled for the long-term efficacy assessment, 7277 (mean age at vaccination, 67.2 years), 813, and 108 were included in the cohorts evaluating efficacy, humoral immune responses, and cell-mediated immune responses, respectively. Efficacy of RZV against HZ through this interim analysis was 84.0% (95% confidence interval [CI], 75.9-89.8) from the start of this follow-up study and 90.9% (95% CI, 88.2-93.2) from vaccination in ZOE-50/70. Annual vaccine efficacy estimates were >84% for each year since vaccination and remained stable through this interim analysis. Anti-gE antibody geometric mean concentrations and median frequencies of gE-specific CD4[2+] T cells reached a plateau at approximately 6-fold above pre-vaccination levels. Conclusions Efficacy against HZ and immune responses to RZV remained high, suggesting that the clinical benefit of RZV in older adults is sustained for at least 7 years post-vaccination.
|
|
| 5. |
- Tigchelaar, Celien, et al.
(författare)
-
Cerebrospinal fluid and plasma concentrations of the inflammatory marker soluble CD27 in a large surgical population
- 2024
-
Ingår i: iScience. - : Elsevier. - 2589-0042. ; 27:6
-
Tidskriftsartikel (refereegranskat)abstract
- Introduction: Soluble CD27 (sCD27) has the potential to serve as a biomarker for diseases involving immune system dysfunction. To inform interpretation of assay results, reference values are needed. So far, analysis of cerebrospinal fluid (CSF) sCD27 has mostly been performed in cohorts of patients with neuroinflammatory disorders, and general control data is missing. The aim of this study was therefore to determine reference ranges and to investigate the influence of factors such as age, comorbidity, blood-CSF-barrier (BCB) function (as assessed by the CSF/plasma albumin quotient (Qalb)) and inflammatory status markers, on CSF and plasma sCD27 concentrations in a relatively neurologically healthy surgical population. Methods: CSF and blood were collected from 486 patients undergoing spinal anaesthesia for elective surgery. Patient demographics, clinical data and the results of routine laboratory analyses were analysed for associations with sCD27 levels in CSF and plasma using a univariable and multivariable model. A healthy sub-cohort was selected based on an American Society of Anesthesiologists (ASA) physical status of I or II (healthy patient or with mild systemic disease), and inter alia, no history of cancer, immunological or neurological disorders, heavy tobacco use, or alcohol abuse. For the whole cohort, and the subpopulation of healthy patients we calculated reference intervals as the central 95% of the data.Results: In the total study group (age range 18 – 92 years, 57% male), median [range] CSF sCD27 concentration was 163 [<50 to 7474] pg/mL and median [range] plasma sCD27 concentration was 4624 [1830 to >400,000] pg/mL. In a multivariable model, plasma sCD27 concentration, age and Qalb were identified as most important for explaining the variability of CSF sCD27 levels. Reference sCD27 concentration intervals in the healthy sub-cohort were < 50 pg/mL – 419 pg/mL for CSF (n=125) and 2344 – 36422 pg/mL for plasma (n=158). Conclusions: Our data from a large group of patients reflecting a broad selection from the general population show that CSF sCD27 concentrations correlate with age and Qalb. These findings provide a solid foundation for interpreting sCD27 as clinical biomarker against a background of multiple socio-demographic and physiological aspects that may influence levels. Further studies to establish clinical CSF sCD27 cut-offs for central nervous system diseases should also account for the influence of age and blood-CSF-barrier function.
|
|
